Skip to Main Content

Paper Details

A large-scale drug screen identifies selective inhibitors of class I HDACs as a potential therapeutic option for SHH medulloblastoma.
Neuro Oncol
22
2019
HDAC, MB, Medulloblastoma, SHH, SHH MB, SHH medulloblastoma, SHH-dependent murine MB cell line, SMB21, SMB21 cells, SMO, Smoothened, cell lines, children, class I HDAC, class I HDACs, histone deacetylase, malignant brain tumors, mouse, murine, patients, quisinostat, sonic, sonic hedgehog, tumor, tumors
Author NameAffiliation
Nathalie Y R AgarBrigham and Women's Hospital, Harvard Medical School
Nathalie Y R AgarDana-Farber Cancer Institute
Nathalie Y R AgarBrigham and Women's Hospital, Harvard Medical School
Jun QiDana-Farber Cancer Institute
Jun QiDana-Farber Cancer Institute and Harvard Medical School
  • 1 - 5

Datasets

Release 1.2